ANP  Vol.2 No.1 , February 2013
Distribution of c-erbB2 Antisense Probe Labeled with Superparamagnetic Iron Oxide Nanoparticles in the Major Organs of Mice on MR Imaging
ABSTRACT

Background: The aim of this study was to investigate the distribution of the c-erbB2 antisense probe labeled with superparamagnetic iron oxide nanoparticles in the major organs of mice by MR imaging. Methods: Sixty BALB/c mice were randomly divided into experimental and control groups. MR scans were performed in each mouse of the experimental group at five different time points (10, 30, 60, 180 and 360 min) after injection of the antisense probe. The signal from each major organ (liver, spleen, heart, kidney and muscle tissue) in comparison with the background signal (signal to noise ratio) was determined at each time point as a measure of the distribution of the antisense probe. Six control mice were killed at each of the same time points and the organs immediately removed for determination of their iron content. Results: After injection of the antisense probe, the highest enrichment of the probe was seen in the spleen, reaching a peak at 180 min, followed by the liver, muscle, heart and kidney. Conclusions: MR imaging can visualize the distribution of c-erbB2 antisense probe labeled with superparamagnetic iron oxide nanoparticles in the major organs of mice, and this may provide the basis for further in vivo studies of MR imaging time and dose selection.


Cite this paper
Wen, Z. , Liu, H. , He, H. , Tan, S. , Wen, M. and Li, S. (2013) Distribution of c-erbB2 Antisense Probe Labeled with Superparamagnetic Iron Oxide Nanoparticles in the Major Organs of Mice on MR Imaging. Advances in Nanoparticles, 2, 16-20. doi: 10.4236/anp.2013.21004.
References
[1]   N. Grenier and P. Brader, “Principles and Basic Concepts of Molecular Imaging,” Pediatric Radiology, Vol. 41, No. 2, 2011, pp. 144-160. doi:10.1007/s00247-010-1835-z

[2]   J. C. Gore, H. C. Manning, C. C. Quarles, et al., “Magnetic Resonance in the Era of Molecular Imaging of Cancer,” Magnetic Resonance Imaging, Vol. 29, No. 5, 2011, pp. 587-600. doi:10.1016/j.mri.2011.02.003

[3]   M. H. Michalski and X. Chen, “Molecular Imaging in Cancer Treatment,” European Journal of Nuclear Medicine and Molecular Imaging, Vol. 38, No. 2, 2011, pp. 358-377. doi:10.1007/s00259-010-1569-z

[4]   M. R. Makowski, A. J. Wiethoff, C. H. Jansen, et al., “Mo lecular Imaging with Targeted Contrast Agents,” Topics in Magnetic Resonance Imaging, Vol. 20, No. 4, 2009, pp. 247-259. doi:10.1097/RMR.0b013e3181ea28b1

[5]   M. A. Pysz, S. S. Gambhir and J. K. Willmann, “Molecular Imaging: Current Status and Emerging Strategies,” Clinical Radiology, Vol. 65, No. 7, 2010, pp. 500-516. doi:10.1016/j.crad.2010.03.011

[6]   R. F. Minchin and D. J. Martin, “Nanoparticles for Molecular Imaging—An Overview,” Endocrinology, Vol. 151, No. 2, 2010, pp. 474-481. doi:10.1210/en.2009-1012

[7]   M. Wen, B. Li, W. Bai, et al., “Application of Atomic Force Microscopy in Morphological Observation of Antisense Probe Labeled with Magnetism,” Molecular Vision, Vol. 14, No. 1, 2008, pp. 114-117.

[8]   M. Wen, B. Li, Y. Ouyang, et al., “Preparation and Quality Test of Superparamagnetic Iron Oxide Labeled Antisense Oligodeoxynucleotide Probe: A Preliminary Study,” Annals of Biomedical Engineering, Vol. 37, No. 6, 2009, pp. 1240-125. doi:10.1007/s10439-009-9683-4

[9]   R. Qiao, J. Zeng, Q. Jia, et al., “Magnetic Iron Oxide Nanoparticle—An Important Cornerstone of MR Molecular Imaging of Tumors,” Acta Physico-Chimica Sinica, Vol. 28, No. 5, 2012, pp. 993-1011.

[10]   K. Chen and X. Chen, “Design and Development of Molecular Imaging Probes,” Current Topics in Medicinal Chemistry, Vol. 10, No. 12, 2010, pp. 1227-1236. doi:10.2174/156802610791384225

[11]   P. Padmanabhan, J. Goggi, R. Bejot, et al., “Molecular Targeting of Breast Cancer: Imaging and Therapy,” Current Pharmaceutical Biotechnology, Vol. 12, No. 4, 2011, pp. 528-538. doi:10.2174/138920111795163959

[12]   J. Capala and K. Bouchelouche, “Molecular Imaging of HER2-Positive Breast Cancer: A Step toward an Individualized Image and Treat Strategy,” Current Opinion in Oncology, Vol. 22, No. 6, 2010, pp. 559-566. doi:10.1097/CCO.0b013e32833f8c3a

[13]   M. E. Seaman, G. Contino, N. Bardeesy, et al., “Molecular Imaging Agents: Impact on Diagnosis and Therapeutics in Oncology,” Expert Reviews in Molecular Medicine, Vol. 12, 2010, p. e20. doi:10.1017/S1462399410001511

[14]   J. W. Bulte and D. L. Kraitchman, “Iron Oxide MR Contrast Agents for Molecular and Cellular Imaging,” NMR in Biomedicine, Vol. 17, No. 7, 2004, pp. 484-499. doi:10.1002/nbm.924

[15]   H. Ittrich, C. Lange, F. Togel, et al., “In Vivo Magnetic Resonance Imaging of Iron Oxide-Labeled, Arterially Injected Mesenchymal Stem Cells in Kidneys of Rats with Acute Ischemic Kidney Injury: Detection and Monitoring at 3T,” Journal of Magnetic Resonance Imaging, Vol. 25, No. 6, 2007, pp. 1179-1191. doi:10.1002/jmri.20925

 
 
Top